Foghorn Therapeutics (FHTX) EBITDA (2019 - 2026)
Foghorn Therapeutics' quarterly EBITDA came in at -$20.0 million in Q1 2026, down 5.68% year-on-year from -$21.2 million in Q1 2025, and up 7.53% quarter-over-quarter from -$21.7 million in Q4 2025.
Foghorn Therapeutics has reported EBITDA for 8 years, with the latest figure at -$20.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 5.68% year-over-year to -$20.0 million; the trailing twelve-month figure through Mar 2026 stood at -$75.5 million (up 5.58% YoY), and the FY2025 full-year result was -$74.4 million, up 13.15% from the prior year.
- EBITDA for Q1 2026 stood at -$20.0 million, up from -$21.7 million in the prior quarter.
- The five-year high for EBITDA was -$13.5 million in Q3 2023, with the low at -$29.4 million in Q1 2023.
- Average EBITDA over 5 years is -$22.8 million, with a median of -$22.8 million recorded in 2024.
- Year-over-year, EBITDA jumped 50.74% in 2023 and plunged 36.28% in 2024.
- Tracing FHTX's EBITDA over 5 years: stood at -$28.0 million in 2022, then increased by 17.74% to -$23.0 million in 2023, then gained by 14.37% to -$19.7 million in 2024, then fell by 9.81% to -$21.7 million in 2025, then increased by 7.53% to -$20.0 million in 2026.
- The last three EBITDA figures came in at -$20.0 million (Q1 2026), -$21.7 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Foghorn Therapeutics | 297.63 Mn | 208.72 Mn | - | -20.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.03 Mn |
| Dec 31, 2025 | -21.66 Mn |
| Sep 30, 2025 | -15.78 Mn |
| Jun 30, 2025 | -17.99 Mn |
| Mar 31, 2025 | -18.96 Mn |
| Dec 31, 2024 | -19.73 Mn |
| Sep 30, 2024 | -18.42 Mn |
| Jun 30, 2024 | -22.82 Mn |
| Mar 31, 2024 | -24.69 Mn |
| Dec 31, 2023 | -23.04 Mn |
| Sep 30, 2023 | -13.52 Mn |
| Jun 30, 2023 | -29.34 Mn |
| Mar 31, 2023 | -29.37 Mn |
| Dec 31, 2022 | -28.01 Mn |
| Sep 30, 2022 | -27.44 Mn |
| Jun 30, 2022 | -29.31 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | -29.12 Mn |
| Sep 30, 2021 | -26.08 Mn |
| Jun 30, 2021 | -23.13 Mn |
| Mar 31, 2021 | -22.97 Mn |
| Dec 31, 2020 | -20.77 Mn |
| Sep 30, 2020 | -18.37 Mn |
| Jun 30, 2020 | -15.72 Mn |
| Mar 31, 2020 | -13.95 Mn |
| Dec 31, 2019 | -15.19 Mn |
| Sep 30, 2019 | -13.10 Mn |